2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia-Reference-Cited by-同舟云学术

2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia

Published:2021-08 Issue:9 Volume:78 Page:960-993
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Virani Salim S.,Morris Pamela B.,Agarwala Anandita,Ballantyne Christie M.,Birtcher Kim K.,Kris-Etherton Penny M.,Ladden-Stirling Amanda B.,Miller Michael,Orringer Carl E.,Stone Neil J.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference107 articles.

1. 2019 methodology for creating expert consensus decision pathways: a report of the American College of Cardiology;Januzzi;J Am Coll Cardiol,2019

2. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines;Grundy;J Am Coll Cardiol,2019

3. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology;Lloyd-Jones;J Am Coll Cardiol,2019

4. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines;Stone;J Am Coll Cardiol,2014

5. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial;Miller;J Am Coll Cardiol,2008

Cited by 171 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia;New England Journal of Medicine;2024-09-12

2. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia;New England Journal of Medicine;2024-09-12

3. Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk;New England Journal of Medicine;2024-09-02

4. ▼Icosapent ethyl for CV risk reduction;Drug and Therapeutics Bulletin;2024-09

5. Simulation model to assess the validity of the clinical portfolio diet score used in the PortfolioDiet.app for dietary self-tracking: a secondary analysis of a randomized controlled trial in hyperlipidemic adults;Frontiers in Nutrition;2024-08-07